Mr. Shaun Flanagan:

Can I just come back on one tiny point? I think the Deputy referred to orphan drugs and medicines that are cost effective and effective. The point that we have been trying to get across is that if that is the decision criteria, we cannot get there. For some of the orphan medicines, if they are to be reimbursed they have to be reimbursed despite the cost effective evidence. I would like to get that nuance out there.